Chidamide Plus Camrelizumab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade

NCT04984018 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

73

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

DRUG: chidamide + camrelizumab

Sponsor

The First Affiliated Hospital of Zhengzhou University